1.2. Adults

Dosage forms, usual dosage regimen, and maximum recommended dosage of exogenous insulin products for adult patients, categorized by time of onset, peak, and duration of action, are summarized in the following:

  • Table 2 10-19
  • Table 3 10-13, 20-23
  • Table 4 10-13, 24, 25
  • Table 5 10-13, 26-31
  • Table 6 10-13, 32-36
  • Table 7 10-13, 37, 38

Lyumjev® and Lyumjev KwikPen® (insulin lispro) is a rapid-acting insulin that was approved in June 2020 for subcutaneous use as an injection or with an insulin pump. It is also approved for intravenous use.19 Semglee® (insulin glargine-yfgn) was approved by the FDA in July 2021, and it is the first FDA approved interchangeable biosimilar insulin product. Semglee® is interchangeable with Lantus® (insulin glargine)